Which has better earnings and valuation, PHAT or TLX?

Telix Pharmaceuticals has higher revenue and earnings than Phathom Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Phathom Pharmaceuticals $175.11M 4.96 -$221.25M -$2.12 N/A Telix Pharmaceuticals $803.79M 4.26 -$7.12M N/A N/A

Is PHAT or TLX more profitable?

Telix Pharmaceuticals has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -76.77%. Company Net Margins Return on Equity Return on Assets Phathom Pharmaceuticals -76.77% N/A -44.29% Telix Pharmaceuticals N/A N/A N/A

Do analysts rate GMTX or PHAT?

Phathom Pharmaceuticals has a consensus price target of $24.50, indicating a potential upside of 124.98%. Given Phathom Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Phathom Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86

Phathom Pharmaceuticals (PHAT) Competitors

$10.89 -0.11 (-1.00%)

Closing price 04:00 PM Eastern

Extended Trading

$10.91 +0.02 (+0.19%)

As of 04:50 PM Eastern

Compare

PHAT vs. TLX, DNLI, BEAM, RCUS, and GMTX

Should you buy Phathom Pharmaceuticals stock or one of its competitors? MarketBeat compares Phathom Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Phathom Pharmaceuticals include Telix Pharmaceuticals (TLX), Denali Therapeutics (DNLI), Beam Therapeutics (BEAM), Arcus Biosciences (RCUS), and Gemini Therapeutics (GMTX). These companies are all part of the "pharmaceutical products" industry.

How does Phathom Pharmaceuticals compare to Telix Pharmaceuticals?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Telix Pharmaceuticals (NASDAQ:TLX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

In the previous week, Phathom Pharmaceuticals and Phathom Pharmaceuticals both had 1 articles in the media. Telix Pharmaceuticals' average media sentiment score of 1.49 beat Phathom Pharmaceuticals' score of 0.00 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Phathom Pharmaceuticals	Neutral
Telix Pharmaceuticals	Positive

Phathom Pharmaceuticals has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.11, meaning that its share price is 111% less volatile than the broader market.

Phathom Pharmaceuticals currently has a consensus target price of $24.50, suggesting a potential upside of 124.98%. Telix Pharmaceuticals has a consensus target price of $21.13, suggesting a potential upside of 109.37%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Phathom Pharmaceuticals is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Telix Pharmaceuticals has higher revenue and earnings than Phathom Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	4.96	-$221.25M	-$2.12	N/A
Telix Pharmaceuticals	$803.79M	4.26	-$7.12M	N/A	N/A

Telix Pharmaceuticals has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -76.77%.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%
Telix Pharmaceuticals	N/A	N/A	N/A

99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 9.3% of Phathom Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Phathom Pharmaceuticals and Telix Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Phathom Pharmaceuticals compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

Denali Therapeutics currently has a consensus price target of $34.25, indicating a potential upside of 46.93%. Phathom Pharmaceuticals has a consensus price target of $24.50, indicating a potential upside of 124.98%. Given Phathom Pharmaceuticals' higher probable upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Denali Therapeutics has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market. Comparatively, Phathom Pharmaceuticals has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market.

In the previous week, Denali Therapeutics and Denali Therapeutics both had 1 articles in the media. Denali Therapeutics' average media sentiment score of 0.00 equaled Phathom Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Denali Therapeutics	Neutral
Phathom Pharmaceuticals	Neutral

92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 12.5% of Denali Therapeutics shares are owned by company insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Denali Therapeutics has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -76.77%. Phathom Pharmaceuticals' return on equity of 0.00% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%

Phathom Pharmaceuticals has lower revenue, but higher earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	11.19	-$512.54M	-$2.88	N/A
Phathom Pharmaceuticals	$175.11M	4.96	-$221.25M	-$2.12	N/A

Summary

Denali Therapeutics beats Phathom Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Phathom Pharmaceuticals compare to Beam Therapeutics?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

Beam Therapeutics has a net margin of -39.66% compared to Phathom Pharmaceuticals' net margin of -76.77%. Phathom Pharmaceuticals' return on equity of 0.00% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

Phathom Pharmaceuticals currently has a consensus target price of $24.50, indicating a potential upside of 124.98%. Beam Therapeutics has a consensus target price of $46.83, indicating a potential upside of 37.18%. Given Phathom Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Phathom Pharmaceuticals is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 9.3% of Phathom Pharmaceuticals shares are owned by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Beam Therapeutics had 6 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 7 mentions for Beam Therapeutics and 1 mentions for Phathom Pharmaceuticals. Beam Therapeutics' average media sentiment score of 1.11 beat Phathom Pharmaceuticals' score of 0.00 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Phathom Pharmaceuticals	Neutral
Beam Therapeutics	Positive

Beam Therapeutics has lower revenue, but higher earnings than Phathom Pharmaceuticals. Beam Therapeutics is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	4.96	-$221.25M	-$2.12	N/A
Beam Therapeutics	$139.74M	25.13	-$79.99M	-$0.68	N/A

Phathom Pharmaceuticals has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.25, suggesting that its share price is 125% more volatile than the broader market.

Summary

Beam Therapeutics beats Phathom Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Phathom Pharmaceuticals compare to Arcus Biosciences?

Arcus Biosciences (NYSE:RCUS) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Phathom Pharmaceuticals has lower revenue, but higher earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	12.42	-$353M	-$3.18	N/A
Phathom Pharmaceuticals	$175.11M	4.96	-$221.25M	-$2.12	N/A

In the previous week, Arcus Biosciences had 4 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 5 mentions for Arcus Biosciences and 1 mentions for Phathom Pharmaceuticals. Arcus Biosciences' average media sentiment score of 1.21 beat Phathom Pharmaceuticals' score of 0.00 indicating that Arcus Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Arcus Biosciences	Positive
Phathom Pharmaceuticals	Neutral

Arcus Biosciences currently has a consensus price target of $35.10, suggesting a potential upside of 43.91%. Phathom Pharmaceuticals has a consensus price target of $24.50, suggesting a potential upside of 124.98%. Given Phathom Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 9.6% of Arcus Biosciences shares are held by company insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Phathom Pharmaceuticals has a net margin of -76.77% compared to Arcus Biosciences' net margin of -156.36%. Phathom Pharmaceuticals' return on equity of 0.00% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-156.36%	-68.97%	-35.27%
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%

Arcus Biosciences has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market. Comparatively, Phathom Pharmaceuticals has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market.

Summary

Phathom Pharmaceuticals beats Arcus Biosciences on 9 of the 17 factors compared between the two stocks.

How does Phathom Pharmaceuticals compare to Gemini Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

Gemini Therapeutics has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -76.77%. Phathom Pharmaceuticals' return on equity of 0.00% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%

75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by company insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Gemini Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the broader market. Comparatively, Phathom Pharmaceuticals has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market.

Gemini Therapeutics has higher earnings, but lower revenue than Phathom Pharmaceuticals. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Phathom Pharmaceuticals	$175.11M	4.96	-$221.25M	-$2.12	N/A

In the previous week, Phathom Pharmaceuticals had 1 more articles in the media than Gemini Therapeutics. MarketBeat recorded 1 mentions for Phathom Pharmaceuticals and 0 mentions for Gemini Therapeutics. Gemini Therapeutics' average media sentiment score of 0.00 equaled Phathom Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Phathom Pharmaceuticals	Neutral

Phathom Pharmaceuticals has a consensus price target of $24.50, indicating a potential upside of 124.98%. Given Phathom Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Phathom Pharmaceuticals beats Gemini Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Phathom Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHAT vs. The Competition

Export

Metric	Phathom Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$868.59M	$3.39B	$6.40B	$12.59B
Dividend Yield	N/A	2.27%	2.67%	5.69%
P/E Ratio	-5.14	19.56	24.51	24.46
Price / Sales	4.96	325.83	553.73	123.23
Price / Cash	N/A	125.35	43.94	55.48
Price / Book	-1.77	8.16	10.70	6.58
Net Income	-$221.25M	$23.89M	$3.57B	$337.29M
7 Day Performance	6.04%	2.54%	0.56%	0.56%
1 Month Performance	-4.39%	4.96%	3.57%	4.44%
1 Year Performance	-0.09%	53.49%	28.48%	31.16%

Phathom Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHAT Phathom Pharmaceuticals	2.1175 of 5 stars	$10.89 -1.0%	$24.50 +125.0%	+4.8%	$868.59M	$175.11M	N/A	110	Analyst Forecast
TLX Telix Pharmaceuticals	4.4855 of 5 stars	$9.22 -0.9%	$21.13 +129.1%	-40.3%	$3.16B	$803.79M	N/A	1,184	News Coverage Positive News
DNLI Denali Therapeutics	2.5196 of 5 stars	$19.54 +0.1%	$34.25 +75.3%	+67.7%	$3.10B	$330.53M	N/A	430	News Coverage Analyst Forecast Gap Up
BEAM Beam Therapeutics	3.2792 of 5 stars	$29.78 +1.3%	$46.83 +57.3%	+94.8%	$3.02B	$139.74M	N/A	510	News Coverage Positive News Gap Up
RCUS Arcus Biosciences	3.0724 of 5 stars	$23.26 +0.3%	$35.10 +50.9%	+176.7%	$2.92B	$247M	N/A	500

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHAT) was last updated on 6/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Phathom Pharmaceuticals (PHAT) Competitors

PHAT vs. TLX, DNLI, BEAM, RCUS, and GMTX

How does Phathom Pharmaceuticals compare to Telix Pharmaceuticals?

Summary

How does Phathom Pharmaceuticals compare to Denali Therapeutics?

Summary

How does Phathom Pharmaceuticals compare to Beam Therapeutics?

Summary

How does Phathom Pharmaceuticals compare to Arcus Biosciences?

Summary

How does Phathom Pharmaceuticals compare to Gemini Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAT vs. The Competition

Phathom Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Phathom Pharmaceuticals (PHAT) Competitors

PHAT vs. TLX, DNLI, BEAM, RCUS, and GMTX

How does Phathom Pharmaceuticals compare to Telix Pharmaceuticals?

Does the media prefer PHAT or TLX?

Which has more volatility and risk, PHAT or TLX?

Do analysts recommend PHAT or TLX?

Which has better earnings and valuation, PHAT or TLX?

Is PHAT or TLX more profitable?

Do institutionals and insiders hold more shares of PHAT or TLX?

Summary

How does Phathom Pharmaceuticals compare to Denali Therapeutics?

Do analysts rate DNLI or PHAT?

Which has more volatility & risk, DNLI or PHAT?

Does the media refer more to DNLI or PHAT?

Do institutionals & insiders have more ownership in DNLI or PHAT?

Is DNLI or PHAT more profitable?

Which has higher earnings and valuation, DNLI or PHAT?

Summary

How does Phathom Pharmaceuticals compare to Beam Therapeutics?

Is PHAT or BEAM more profitable?

Do analysts prefer PHAT or BEAM?

Do institutionals and insiders believe in PHAT or BEAM?

Does the media prefer PHAT or BEAM?

Which has stronger earnings & valuation, PHAT or BEAM?

Which has more volatility & risk, PHAT or BEAM?

Summary

How does Phathom Pharmaceuticals compare to Arcus Biosciences?

Which has better valuation and earnings, RCUS or PHAT?

Does the media favor RCUS or PHAT?

Do analysts rate RCUS or PHAT?

Do insiders & institutionals hold more shares of RCUS or PHAT?

Is RCUS or PHAT more profitable?

Which has more volatility and risk, RCUS or PHAT?

Summary

How does Phathom Pharmaceuticals compare to Gemini Therapeutics?

Is GMTX or PHAT more profitable?

Do insiders and institutionals believe in GMTX or PHAT?

Which has more volatility & risk, GMTX or PHAT?

Which has preferable valuation and earnings, GMTX or PHAT?

Does the media refer more to GMTX or PHAT?

Do analysts rate GMTX or PHAT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAT vs. The Competition

Phathom Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools